IDRA is one of the few companies still working on TLR agonists and antagonists: http://finance.yahoo.com/news/Idera-Announces-Presentation-bw-1420413332.html?x=0&l=1 The programs in HCV (#msg-62376531) and psoriasis (#msg-65402572) haven’t worked out; maybe the one in atherosclerosis will do better.